ArriVent BioPharma (AVBP) Corporate presentation summary

Strategic focus and pipeline overview

• Accelerating a differentiated oncology pipeline through global partnerships and innovative assets.

• Lead program firmonertinib has Breakthrough Therapy and Orphan designation for 1L EGFR exon 20 insertion mutant NSCLC.

• Multiple clinical assets in development, including next-generation ADCs targeting solid tumors.

• Completed pivotal study enrollment for firmonertinib in EGFR exon 20 insertion NSCLC.

• Initiated global Phase 3 study for firmonertinib in EGFR PACC mutations.

Firmonertinib clinical development and results

• Structurally differentiated EGFR inhibitor, active against classical and uncommon mutations, with strong CNS penetration.

• Approved in China for classical EGFR mutations and second-line exon 20 insertions; global pivotal Phase 3 studies ongoing.

• FAVOUR study showed confirmed ORR of 78.6% in treatment-naïve EGFR exon 20 insertion NSCLC, with median DoR of 15.2 months.

• FURVENT Phase 3 trial targets 1L NSCLC with EGFR exon 20 insertions, primary endpoint PFS.

• FURTHER Phase 1b in EGFR PACC mutations showed confirmed ORR up to 81.8% and median PFS of 16.0 months at 240 mg.

Safety and CNS activity

• Firmonertinib demonstrated manageable safety profile with no grade 4-5 TRAEs in PACC cohorts.

• CNS activity observed, including 41% complete CNS response rate in PACC cohort.

• Most responses were rapid and durable, with some ongoing beyond 26 months.